Momchilo Vuyisich

The paper develops and validates a Disease Risk Score (DRS) framework using metatranscriptomics data to assess disease risk, showing significant risk enrichment for 15 diseases in an independent cohort.

This study shows the human gut microbiome remains stable in composition and function for up to six months, with resilience to short-term disruptions like colonoscopy preparation.

The paper develops gut microbial functional pathway scores from metatranscriptome data to identify molecular markers associated with irritable bowel syndrome and its subtypes.

The paper develops synthetic control samples for metatranscriptomic diagnostics, validated in a clinical lab with high reproducibility and signal strength.

The paper develops microbial functional pathway scores from metatranscriptomic data to assess oral health and disease phenotypes using saliva samples.

This paper presents a data-driven precision nutrition platform that improves clinical outcomes and risk scores for IBS, depression, anxiety, and T2D through personalized dietary recommendations based on gut microbiome and host gene expression data.

The paper shows gut microbiome activity predicts individual glycemic responses to meals, beyond diet and body metrics.

This paper develops an aging clock using human and microbial gene expression data, showing associations between biological age and lifestyle factors.

The paper develops a clinically validated transcriptome test using capillary blood for global systems biology studies, enabling affordable and accessible gene expression analysis.

Viomega is a robust, automated stool metatranscriptomic method for population-scale studies, demonstrating stability and consistency across 10,000 samples.